Reviews and feature articleKey findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study
Section snippets
Burden of illness and asthma-related QoL
High rates of health care use (HCU) and medication use were observed in the TENOR cohort. In the 3 months before enrollment, 5% and 15% of adults, 10% and 17% of adolescents, and 9% and 22% of children had at least 1 asthma hospitalization or emergency department (ED) visit, respectively, and in addition, almost half the adults and children and approximately 40% of adolescents reported oral corticosteroid (OCS) bursts and unscheduled visits for asthma.4 Approximately 10% of patients across all
Lung function
Because optimal control of asthma remains elusive in many children, TENOR compared the rates of asthma exacerbations by lung function in children versus adolescents/adults who were taking recommended long-term controller asthma medications.15 Zeiger et al15 showed that approximately 30% to 40% of all patients with abnormal lung function (FEV1 ≤80%) had a course of OCSs in the 3 months before the 12- and 18-month follow-up visits (Table II). By the 24-month follow-up visit, more than half (52%)
Asthma control and exacerbations: TENOR main outcomes
TENOR analyses have consistently shown that a recent asthma exacerbation is the strongest predictor for a future exacerbation.28, 29 In multivariate analyses conducted in children (n = 563), a future severe asthma exacerbation at 6 months was most strongly predicted by a recent severe exacerbation (odds ratio [OR], 3.08; 95% CI, 2.21-4.28), followed by having 3 to 4 allergic triggers (OR, 2.05; 95% CI, 1.31-3.20). Other significant predictors of future severe asthma exacerbation were
IgE and allergen sensitization
It is estimated that the population-based proportion of asthma cases attributable to atopy is between 50%-60%.32, 33 IgE plays a key role in mediating the allergic response in asthma,34 and populations of patients with asthma have increased total IgE levels compared with nonasthmatic populations. In TENOR male subjects, children, smokers, nonwhite racial/ethnic groups, and adults with childhood-onset asthma had higher IgE levels compared with nonasthmatic or nonallergic populations; total IgE
Special populations examined within TENOR
The TENOR study is unique largely because it identified important subgroups and possible asthma phenotypes within the study population, which may help improve asthma care in these groups.
Clinical tools
Developing reliable and predictive clinical tools may help physicians identify those patients at increased risk for hospitalization/ED visits and loss of productivity/activity. An innovative TENOR-derived risk score was developed that could reliably predict asthma-related hospitalizations/ED visits in adults with severe or difficult-to-treat asthma.50 In an analysis of 2821 adults, 239 (8.5%) reported asthma-related hospitalizations/ED visits at follow-up. Variables that predicted increased
Genetic studies
In the first genome-wide association analysis in patients with severe or difficult-to-treat asthma to uncover the association of DNA variants with asthma susceptibility, 473 TENOR patients and 1892 population control subjects were studied for 292,443 single nucleotide polymorphisms (SNPs) for association with asthma.48 Total serum IgE levels, FEV1 and FVC values, and FEV1/FVC ratios in identified candidate regions in 473 TENOR patients and 363 control subjects without a history of asthma were
Conclusions
Since its launch in 2001, TENOR has provided the scientific and clinical community with important lessons in understanding the natural history, asthma morbidity and burden, and unmet needs in patients with severe or difficult-to-treat asthma for the purpose of improving asthma-related health outcomes in this understudied population. The key observations and clinical implications from TENOR have potentially important clinical implications for health care providers (Table IV).∗
References (54)
- et al.
Design and baseline characteristics of the Epidemiology And Natural History Of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma
Ann Allergy Asthma Immunol
(2004) - et al.
Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma
J Allergy Clin Immunol
(2007) - et al.
Severity assessment in asthma: an evolving concept
J Allergy Clin Immunol
(2005) - et al.
Characterization of the severe asthma phenotype by the National Heart, Lung and Blood Institute's Severe Asthma Research Program
J Allergy Clin Immunol
(2007) - et al.
Comparison of asthma exacerbations in pediatric and adult patients with severe or difficult-to-treat asthma
J Allergy Clin Immunol
(2009) - et al.
Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma
Respir Med
(1999) - et al.
Significant variability in response to inhaled corticosteroids for persistent asthma
J Allergy Clin Immunol
(2002) - et al.
Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease
J Allergy Clin Immunol
(2007) - et al.
Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma
J Allergy Clin Immunol
(2009) - et al.
Recent asthma exacerbations: a key predictor of future exacerbations
Respir Med
(2007)
Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey
J Allergy Clin Immunol
Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma
Ann Allergy Asthma Immunol
Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma
J Allergy Clin Immunol
Asthma in older adults: observations from the Epidemiology And Natural History Of Asthma: Outcomes And Treatment Regimens (TENOR) study
Ann Allergy Asthma Immunol
Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study
Chest
Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation
J Allergy Clin Immunol
Decreased response to inhaled steroids in overweight and obese asthmatic children
J Allergy Clin Immunol
Effect of weight change on asthma-related health outcomes in patients with severe or difficult-to-treat asthma
Respir Med
Racial disparities in asthma-related health outcomes in severe or difficult-to-treat asthma
Ann Allergy Asthma Immunol
Subspecialty differences in asthma characteristics and management
Mayo Clin Proc
Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma
Value Health
Impact of childhood asthma on health
Pediatrics
Features that distinguish those who die from asthma from community controls with asthma
J Asthma
Association of asthma control with health care utilization: a prospective evaluation
Am J Respir Crit Care Med
Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society
Am J Respir Crit Care Med
National Asthma Education and Prevention Program, expert panel report 2: guidelines for the diagnosis and management of asthma
Expert panel report: guidelines for the diagnosis and management of asthma. Update on selected topics—2002
J Allergy Clin Immunol
Cited by (0)
Genentech, Inc (South San Francisco, Calif), and Novartis Pharmaceuticals (East Hanover, NJ) provided support for the preparation of this manuscript.
Disclosure of potential conflict of interest: B. E. Chipps has consultant arrangements with Alcon, Genentech, AstraZeneca, GlaxoSmithKline, Meda, Novartis, Sunovion, Merck-Schering, ISTA, Quintiles, and Dey; is on the speakers' bureau for Alcon, Genentech, AstraZeneca, GlaxoSmithKline, Meda, Novartis, Sunovion, Merck-Schering, ISTA, and Dey; has received grants for clinical research from Genentech, AstraZeneca, GlaxoSmithKline, Novartis, Sunovion, and Merck-Schering; and has received grants for education activities from Alcon, Genentech, AstraZeneca, GlaxoSmithKline, and Novartis. R. S. Zeiger has consultant arrangements with AstraZeneca, Aerocrine, Genentech, GlaxoSmithKline, Novartis, Sunovion, Schering-Plough, and MedImmune and has received research support from Aerocrine, Genentech, GlaxoSmithKline, and Merck and Co. L. Borish has received honoraria from Merck; has consultant arrangements with Genentech, Endo Pharmaceuticals, Regeneron, Cephalon, Pfizer, and Hoffman-LaRoche; has received research support from Merck and Genentech; is on committees for the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology; and is a volunteer for the Charlottesville Free Clinic. M. L. Hayden has received speaker's honoraria from TEVA, Merck and Co, and Dey Labs and has consultant arrangements with Sunovion. D. P. Miller's employer has Genentech as a client. E. R. Bleecker has consultant arrangements with Genentech and has received research support from Genentech. F. E. R. Simons has received research support from the Canadian Institutes of Health Research. S. J. Szefler has consultant arrangements with GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from the National Institutes of Health/National Heart, Lung, and Blood Institute's Childhood Management Program (CAMP); the National Heart, Lung, and Blood Institute's Childhood Asthma Research and Education (CARE); the National Institutes of Health/National Heart, Lung, and Blood Institute's Asthma Clinical Research Network (ACRN); the National Institutes of Health/National Institutes of Allergy and Infectious Disease's Inner City Asthma Consortium (ICAC); GlaxoSmithKline; the National Institutes of Health/National Heart, Lung, and Blood Institute's Asthma Net; and a National Institute of Environmental Health Sciences/Environmental Protection Agency's Childhood Environmental Health Center grant. T. Haselkorn has been a paid consultant to Genentech, Inc since 2002. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
Dr Yegin is currently affiliated with Actelion Pharmaceuticals.
- ‡
For a complete list of TENOR Study Group members, please contact Genentech, Inc.